drugset / Trial / NCT02646800

Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp

NCT02646800

Phase 4 Terminated 105 enrolled Astellas Pharma Inc
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the safety and efficacy of intravenous micafungin for the treatment of adult patients in China infected by Candida spp or Aspergillus spp.

Timeline

Start
2014-03-21
Primary completion
2014-12-21
Completion
2014-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Micafungin Peptide Intravenous